Studies Currently Enrolling
Clinical trials are key to advancing the health care landscape and how we treat illnesses. Banner Alzheimer’s Institute (BAI) is proud to offer research studies to patients and people in the community. Studies here are focused on Alzheimer’s disease and other dementias. There are ways you can help research whether you have memory loss or not.Ages Eligible for Study: 47-68 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes
This study is sponsored by the National Institutes of Health (NIH) and is a long-term study that seeks to better understand the course of Alzheimer’s disease before clinical symptoms emerge. This brain imaging study, a collaboration with Mayo Clinic, will follow individuals indefinitely. The purpose is to observe the course of aging in participants with different genetic risk levels of developing different memory problems. The study includes visits every two years. Imaging visits include MRIs and PET scans. The study also includes optional lumbar punctures. Participants do not require a study partner.
GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype (NCT02564692)
TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD) (NCT04004767)
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NC04468659)
The Kronos Early Estrogen Prevention Study (KEEPS) (NCT03718494)
Alzheimer’s Disease Core Center (ADCC) (NCT01421420)
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol (NCT02854033)
Learn more: ADNI 3
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (Hope4MCI) (NCT03486938)
A Study to Confirm Safety and Efficacy of BAN2401 in Participants With Early Alzheimer's Disease (Clarity AD) (NCT03887455)
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 (NCT04241068)
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) (NCT04437511)